The genetics of cardiac failure: Role of a G protein-coupled receptor polymorphism in therapeutic response in an Indian population
Background and aim: The incidence of heart failure (HF) is rising to epidemic proportions in developing countries like India. A lack of adequate Indian studies underscores the importance of pursuing research into HF in an Indian population. G protein-coupled receptor kinase 5 (GRK5) Gln41>Leu (rs2230345) polymorphism was reported as a genetic modifier associated with survival in HF patients. A prospective study was conducted to investigate the association of GRK5 Gln41>Leu polymorphism with response to β-blocker therapy in Indian HF patients.
Methods: HF patients (n=584) were recruited for the study. The patients were genotyped by tetra-primerbased allele specific PCR and confirmed with Sanger sequencing. The HF patients were evaluated for GRK5 gene expression and followed-up for ~3 years. Drug dosages, cardiac output and hospitalization-free survival were evaluated as study outcomes. HF subgroups (i.e.,systolic or diastolic dysfunction, biventricular dysfunction and pulmonary artery hypertension)were also analyzed in association with hospital-free survival.
Results: HF patients showed genotype frequencies of AT (15%) and TT (1%). AT/TT genotype carriers showed downregulated GRK5 gene expression and significant reduction in carvedilol drug dosage (p=0.0001). Moreover, AT/TT genotype carriers on β-blockers showed improved ejection fraction from 27% to 36% (p=0.0007) and increased hospitalization-free survival in comparison to other HF patients. HF patients with AA genotype showed an increased rate of hospital admission in comparison with patients with the AT/TT genotype. HF subgroups with the AT/TT genotype showed an increased hospitalization-free survival versus subgroups with the AA genotype.
Conclusions: GRK5 Gln41>Leu polymorphism in response to β-blocker therapy improved cardiac function in HF patients.
Relevance for patients: This study presents a comprehensive clinicofunctional pharmacogenetic characterization of GRK5 Gln41>Leu polymorphism in a cohort of Indian HF patients. GRK5 Gln41>Leu polymorphism can confer improved cardiac function and reduce hospitalization, thus improving the quality of life in HF patients.
[1] Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019;139:e56-528.
[2] Huffman MD, Prabhakaran D. Heart Failure: Epidemiology and Prevention in India. Natl Med J India 2010;23:283-8.
[3] Guo M, Guo G, Ji X. Genetic Polymorphisms Associated with Heart Failure: A Literature Review. J Int Med Res 2016;44:15-29.
[4] Seth S, Ramakrishnan S, Parekh N, Karthikeyan G, Singh S, Sharma G. Heart Failure Guidelines for India: Update 2017. J Pract Cardiovasc Sci 2017;3:133-8.
[5] Bristow MR. Beta-Adrenergic Receptor Blockade in Chronic Heart Failure. Circulation 2000;101:558-69.
[6] Steinberg SF. The Molecular Basis for Distinct BetaAdrenergic Receptor Subtype Actions in Cardiomyocytes. Circ Res 1999;85:1101-11.
[7] Madamanchi A. Beta-adrenergic Receptor Signaling in Cardiac Function and Heart Failure. Mcgill J Med 2007;10:99-104.
[8] de Lucia C, Eguchi A, Koch WJ. New Insights in Cardiac β-Adrenergic Signaling during Heart Failure and Aging. Front Pharmacol 2018;9:904.
[9] Zhang Y, Matkovich SJ, Duan X, Gold JI, Koch WJ, Dorn GW 2nd. Nuclear Effects of G-Protein Receptor Kinase 5 on Histone Deacetylase 5-Regulated Gene Transcription in Heart Failure. Circ Heart Fail 2011;4:659-68.
[10] Mangmool S, Parichatikanond W, Kurose H. Therapeutic Targets for Treatment of Heart Failure: Focus on GRKs and β-Arrestins Affecting β-AR Signaling. Front Pharmacol 2018;9:1336.
[11] Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 Polymorphism that Inhibits Beta-Adrenergic Receptor Signaling is Protective in Heart Failure. Nat Med 2008;14:510-7.
[12] Dorn GW 2nd, Liggett SB. Pharmacogenomics of BetaAdrenergic Receptors and their Accessory Signaling Proteins in Heart Failure. Clin Transl Sci 2008;1:255-62.
[13] King M, Kingery J, Casey B. Diagnosis and Evaluation of Heart Failure. Am Fam Physician 2012;85:1161-8.
[14] Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.e14.
[15] Johnson AE, Hanley-Yanez K, Yancy CW, Taylor AL, Feldman AM, McNamara DM. Adrenergic Polymorphisms and Survival in African Americans With Heart Failure: Results From A-HeFT. J Card Fail 2019;25:553-60.
[16] Kang S, Hong X, Ruan CW, Yu P, Yu SS, Chen M, et al. Effects of GRK5 and ADRB1 Polymorphisms Influence on Systolic Heart Failure. J Transl Med 2015;13:44.
[17] Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, Dorn GW 2nd. Clinical and Genetic Modifiers of Long-Term Survival in Heart Failure. J Am Coll Cardiol 2009;54:432-44.
[18] Vinge LE, Øie E, Andersson Y, Grøgaard HK, Andersen G, Attramadal H. Myocardial Distribution and Regulation of GRK and Beta-Arrestin Isoforms in Congestive Heart Failure in Rats. Am J Physiol Heart Circ Physiol 2001;281:H2490-9.
[19] Chen EP, Bittner HB, Akhter SA, Koch WJ, Davis RD. Myocardial Function in Hearts with Transgenic Overexpression of the G Protein-Coupled Receptor Kinase 5. Ann Thorac Surg 2001;71:1320-4.
[20] Ishizaka N, Alexander RW, Laursen JB, Kai H, Fukui T, Oppermann M, et al. G Protein-Coupled Receptor Kinase 5 in Cultured Vascular Smooth Muscle Cells and Rat Aorta. Regulation by Angiotensin II and Hypertension. J Biol Chem 1997;272:32482-8.
[21] Sorriento D, Santulli G, Fusco A, Anastasio A, Trimarco B, Iaccarino G. Intracardiac Injection of AdGRK5-NT Reduces Left Ventricular Hypertrophy by Inhibiting NF-kappaB-Dependent Hypertrophic Gene Expression. Hypertension 2010;56:696-704.
[22] Hendrickx JO, van Gastel J, Leysen H, Santos-Otte P, Premont RT, Martin B, et al. GRK5-a Functional Bridge between Cardiovascular and Neurodegenerative Disorders. Front Pharmacol 2018;9:1484.
[23] Rasool AH, Rahman AR, Ismail R, Hatim S, Abdullah AR, Singh R, et al. Ethnic Differences in Response to NonSelective Beta-Blockade among Racial Groups in Malaysia. Int J Clin Pharmacol Ther 2000;38:260-9.
[24] Ramu P, Kumar KN, Shewade DG, Swaminathan RP, Dutta TK, Balachander J, et al. Polymorphic Variants of Beta1 Adrenergic Receptor Gene (Ser49Gly and Arg389Gly) in Healthy Tamilian Volunteers. Indian J Med Res 2010;132:62-6.
[25] Kumar KN, Ramu P, Rajan S, Shewade DG, Balachander J, Adithan C. Genetic Polymorphisms of Beta1 Adrenergic Receptor and their Influence on the Cardiovascular Responses to Metoprolol in a South Indian Population. J Cardiovasc Pharmacol 2008;52:459-66.
[26] Huang J, Li C, Song Y, Fan X, You L, Tan L, et al. ADRB2 Polymorphism Arg16Gly Modifies the Natural Outcome of Heart Failure and Dictates Therapeutic Response to β-Blockers in Patients with Heart Failure. Cell Discov 2018;4:57.
[27] Chavey WE 2nd. The Importance of Beta Blockers in the Treatment of Heart Failure. Am Fam Physician 2000;62:2453-62.
[28] Cesario DA, Fonarow GC. Beta-Blocker Therapy for Heart Failure: The Standard of Care. Rev Cardiovasc Med 2002;3:14-21.
[29] Dézsi CA, Szentes V. The Real Role of β-Blockers in Daily Cardiovascular Therapy. Am J Cardiovasc Drugs 2017;17:361-73.
[30] Kurnik D, Cunningham AJ, Sofowora GG, Kohli U, Li is not Associated with Sensitivity to Beta(1)- Adrenergic Blockade in Humans. Pharmacogenomics 2009;10:1581-7.
[31] Sardana M, Syed AA, Hashmath Z, Phan TS, Koppula MR, Kewan U, et al. Beta-Blocker use is Associated with Impaired Left Atrial Function in Hypertension. J Am Heart Assoc 2017;6:e005163.
[32] Ko DT, Hebert PR, Coffey CS, Curtis JP, Foody JM, Sedrakyan A, et al. Adverse effects of Beta-Blocker Therapy for Patients with Heart Failure: A Quantitative Overview of Randomized Trials. Arch Intern Med 2004;164:1389-94.
[33] DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O’Keefe JH. Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol). Am J Cardiol 2013;111:765-9.
[34] Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Raval U, Webster J, et al. Effects of Carvedilol on Left Ventricular Remodelling in Chronic Stable Heart Failure: A Cardiovascular Magnetic Resonance Study. Heart 2004;90:760-4.